Heartflow, a cardiac CT AI vendor, files for a $100 million IPO after notable adoption and revenue growth.
Key Details
- 1Heartflow filed SEC documents for a $100M IPO following positive coverage news for its AI CT software.
- 2Radiology benefits manager EviCore and proposed Medicare Fee Schedule support are expected to boost future adoption.
- 3Heartflow's CT-based platform has been used on over 400,000 patients, including 132,000 last year.
- 4Company reported $126 million in revenue for 2023, up 44% year-over-year, but posted a $32.3 million quarterly loss in early 2024.
- 5Market opportunity for Heartflow's AI solutions estimated at $5 billion in the U.S. annually.
- 6IPO proceeds will be used for debt payment, sales, R&D, and general operations.
Why It Matters
Heartflow's IPO marks a major milestone in the maturation of radiology-focused AI companies and demonstrates growing clinical and payer acceptance of imaging AI tools. The public funding and Medicare consideration signal greater integration of AI in CT-based cardiovascular diagnostics.
Source
Radiology Business
Related News
•AuntMinnie
AI-Based Slab Reconstruction Streamlines Digital Breast Tomosynthesis
AI-driven slab reconstruction in DBT improves workflow efficiency without compromising diagnostic accuracy in breast cancer screening.
•AuntMinnie
AI Model Predicts Dosimetry for Lu-177 PSMA Therapy Using PET/CT
A machine learning PET/CT model shows promise for predicting radiation dose prior to Lu-177 PSMA therapy in prostate cancer patients.
•Radiology Business
DeepHealth's Prostate AI Gains FDA Clearance for MRI Workflows
DeepHealth, a RadNet subsidiary, received FDA clearance for its AI solution to assist prostate cancer detection and MRI workflow.